[ad_1] Regeneron Pharmaceuticals (NASDAQ:REGN) mentioned on Monday its bispecific antibody Ordspono (odronextamab) has been cleared by the European Commission for the therapy of relapsed/refractory follicular lymphoma…
[ad_1] Regeneron Pharmaceuticals (NASDAQ:REGN) mentioned on Monday its bispecific antibody Ordspono (odronextamab) has been cleared by the European Commission for the remedy of relapsed/refractory follicular lymphoma…
